[1]Armstrong-James, D, G. Meintjes, and G.D. Brown..A neglected epidemic: fungal infections in HIV/AIDS[J]. [J].Trends in microbiology,, 2014, 22:120-127. [2]Mayer, KH., C.L. Karp, and P.G. Auwaerter..Coinfection with HIV and tropical infectious diseases. I. Protozoal pathogens.[J].Clinical Infectious Diseases, 2007, 45:1208-1213. [3]Gullo, F, et al., .Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment[J].European journal of clinical microbiology & infectious diseases, 2013, 32:1377-1391. [4]Park, B J., et al.,. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS.[J].Aids, 2009, 23:525-530. [5]Palella Jr, F J., et al.,. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.[J].New England Journal of Medicine, 1998., 338:853-860. [6]Antinori, S , et al., .Cryptococcus neoformans infection in a cohort of Italian AIDS patients: natural history, early prognostic parameters, and autopsy findings .[J].European Journal of Clinical Microbiology and Infectious Diseases,, 2001., 20:711--717. [7]Kaplan, J E., et al.. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.[J].Clinical Infectious Diseases,, 2000, 30:S5-S14. [8]Mirza, S A., et al.. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992–2000.[J].Clinical infectious diseases, 2003, 36:789-794. [9]Dromer, F, et al..Epidemiology of HIV-associated cryptococcosis in France (1985–2001): comparison of the pre-and post-HAART eras. [J].Aids, 2004., 18:555-562.. [10]Michaels, S H., R. Clark, and P. Kissinger..Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.[J].New England Journal of Medicine, 1998, 339:405-406. [11]Chen, M, et al..Molecular epidemiology of Cryptococcus neoformans species complex isolates from HIV-positive and HIV-negative patients in southeast China. [J].Frontiers of Medicine in China, 2010, 4:117-126. [12]Bratton, E W., et al..Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. [J].PloS one, 2012., 7:e43582.-. [13]Khayhan, K, et al..Geographically structured populations of Cryptococcus neoformans variety grubii in Asia correlate with HIV status and show a clonal population structure.[J].PloS one, 2013, 8:e72222.-. [14]Huang, L, et al..HIV-associated Pneumocystis pneumonia.,.: p. -.[J].Proceedings of the American Thoracic Society, 2011, 8:294-300. [15]Phair, J, et al..The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1.[J].New England Journal of Medicine, 1990, 322:161-165.. [16]Kaplan, J E. and K.K. Holmes., Guidelines for Preventing Opportunistic Infections among HIV-Infected Persons—2002: Recommendations of the US Public Health Service and the Infectious Diseases Society of America*. ,. : p. -.[J].Annals of internal medicine, 2002, 137:435-478. [17]Hay, J W., D.H. Osmond, and M.A. Jacobson..Projecting the medical costs of AIDS and ARC in the United States. . : p. -.[J].JAIDS Journal of Acquired Immune Deficiency Syndromes,, 1988, 1:466-485. [18]Morris, A, et al.., Current epidemiology of Pneumocystis pneumonia. ,. : p. .[J].Emerging infectious diseases, 2004, 10:1713-. [19]Thomas Jr, C F. and A.H. Limper.Pneumocystis pneumonia.[J].New England Journal of Medicine, 2004, 350:2487-2498. [20]Patel, PK., et al.The changing epidemiology of oropharyngeal candidiasis in patients with HIV/AIDS in the era of antiretroviral therapy.[J].AIDS research and treatment, 2012, 2012:-. [21]Sobel, J D., et al., .The Evolution of Candida Species and Fluconazole Susceptibility among Oral and Vaginal Isolates Recovered from Human Immunodeficiency Virus (HIV)—Seropositive and At-Risk HIV-Seronegative Women.[J].Journal of Infectious Diseases, 2001, 183:286-293.. [22]Alborzi, A and M.A. Davarpanah.Distributions and antifungal susceptibility of Candida species from mucosal sites in HIV positive patients. [J].Archives of Iranian medicine, 2010, 13:282.-. [23]Wong, S et al.,., Differences in clinical and laboratory diagnostic characteristics of penicilliosis marneffei in human immunodeficiency virus (HIV)-and non-HIV-infected patients.[J].Journal of clinical microbiology, 2001, 39:4535-4540.. [24]Huang, L, et al.Suspected Pneumocystis carinii pneumonia with a negative induced sputum examination. Is early bronchoscopy useful? [J].American journal of respiratory and critical care medicine, 1995, 151:1866-1871. [25]Day, J N., et al..Combination antifungal therapy for cryptococcal meningitis.[J].New England Journal of Medicine,, 2013, 368:1291-1302. [26]Yao, Z, W. Liao, and R. Chen.Management of cryptococcosis in non-HIV-related patients.[J].Medical mycology, 2005, 43:245-251. [27]Bisson, G P., et al..Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis.[J].Clinical infectious diseases, 2013, 56:1165-1173. [28]Cornely, O, et al..ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non‐neutropenic adult patients. , . : p. -.[J].Clinical Microbiology and Infection, 2012, 18:19-37. [29]Sharma, P C., et al..In Vitro Antifungal Susceptibility Pattern of Oropharyngeal and Oesophageal Candida Species in HIV Infected Patients.[J].International Journal of Health Sciences and Research (IJHSR), 2013, 3:1-6. [30]Supparatpinyo, K, et al..A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus.[J].New England Journal of Medicine, 1998, 339:1739-1743. [31]Hung, C-C., et al..Discontinuation of secondary prophylaxis for penicilliosis marneffei in AIDS patients responding to highly active antiretroviral therapy.[J].Aids, 2002, 16:672-673. [32]Mayer, K H., C.L. Karp, and P.G. Auwaerter.Coinfection with HIV and tropical infectious diseases. II. Helminthic, fungal, bacterial, and viral pathogens.[J].Clinical Infectious Diseases, 2007, 45:1214-1220. [33]Cao, Y, et al..In vitro activity of baicalein against Candida albicans biofilms.[J].International journal of antimicrobial agents, 2008, 32:73-77. [34]Cowan, M M..Plant products as antimicrobial agents. [J].Clinical microbiology reviews, 1999, 12:564-582. [35]Motsei, M,et al..Screening of traditionally used South African plants for antifungal activity against Candida albicans.[J].Journal of ethnopharmacology, 2003, 86:235-241. [36]Hamza, O J., et al..Antifungal activity of some Tanzanian plants used traditionally for the treatment of fungal infections.[J].Journal of ethnopharmacology, 2006, 108:124-132. [37]Hu, H, et al..Impact of Eating Probiotic Yogurt on Colonization by Candida Species of the Oral and Vaginal Mucosa in HIV-Infected and HIV-Uninfected Women.[J].Mycopathologia, 2013, 176:175-181.. [38]Saag, M S., et al..Practice guidelines for the management of cryptococcal disease.[J].Clinical Infectious Diseases, 2000, 30:710-718.